187 related articles for article (PubMed ID: 38810705)
1. To see or not to see: In vivo nanocarrier detection methods in the brain and their challenges.
Wehn AC; Krestel E; Harapan BN; Klymchenko A; Plesnila N; Khalin I
J Control Release; 2024 Jul; 371():216-236. PubMed ID: 38810705
[TBL] [Abstract][Full Text] [Related]
2. Nanotechnology-based Drug Delivery for Alzheimer's and Parkinson's Diseases.
Nguyen-Thi PT; Ho TT; Nguyen TT; Vo GV
Curr Drug Deliv; 2024; 21(7):917-931. PubMed ID: 37424345
[TBL] [Abstract][Full Text] [Related]
3. Multifunctional Nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging.
Bhaskar S; Tian F; Stoeger T; Kreyling W; de la Fuente JM; Grazú V; Borm P; Estrada G; Ntziachristos V; Razansky D
Part Fibre Toxicol; 2010 Mar; 7():3. PubMed ID: 20199661
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticles as carriers for drug delivery of macromolecules across the blood-brain barrier.
Tosi G; Duskey JT; Kreuter J
Expert Opin Drug Deliv; 2020 Jan; 17(1):23-32. PubMed ID: 31774000
[No Abstract] [Full Text] [Related]
5. Standardization of research methods employed in assessing the interaction between metallic-based nanoparticles and the blood-brain barrier: Present and future perspectives.
Ross AM; Mc Nulty D; O'Dwyer C; Grabrucker AM; Cronin P; Mulvihill JJE
J Control Release; 2019 Feb; 296():202-224. PubMed ID: 30664977
[TBL] [Abstract][Full Text] [Related]
6. Current insights on lipid nanocarrier-assisted drug delivery in the treatment of neurodegenerative diseases.
Teixeira MI; Lopes CM; Amaral MH; Costa PC
Eur J Pharm Biopharm; 2020 Apr; 149():192-217. PubMed ID: 31982574
[TBL] [Abstract][Full Text] [Related]
7. A neoteric annotation on the advances in combination therapy for Parkinson's disease: nanocarrier-based combination approach and future anticipation. Part II: nanocarrier design and development in focus.
Unnithan D; Sartaj A; Iqubal MK; Ali J; Baboota S
Expert Opin Drug Deliv; 2024 Mar; 21(3):437-456. PubMed ID: 38507231
[TBL] [Abstract][Full Text] [Related]
8. Transferrin-conjugated nanoparticles of poly(lactide)-D-alpha-tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood-brain barrier.
Gan CW; Feng SS
Biomaterials; 2010 Oct; 31(30):7748-57. PubMed ID: 20673685
[TBL] [Abstract][Full Text] [Related]
9. Nanotechnologies: a strategy to overcome blood-brain barrier.
De Rosa G; Salzano G; Caraglia M; Abbruzzese A
Curr Drug Metab; 2012 Jan; 13(1):61-9. PubMed ID: 22292810
[TBL] [Abstract][Full Text] [Related]
10. Recent progress of drug nanoformulations targeting to brain.
Khan AR; Yang X; Fu M; Zhai G
J Control Release; 2018 Dec; 291():37-64. PubMed ID: 30308256
[TBL] [Abstract][Full Text] [Related]
11. Nanotechnology-based delivery of therapeutics through the intranasal pathway and the blood-brain barrier for Alzheimer's disease treatment.
Boyetey MB; Choi Y; Lee HY; Choi J
Biomater Sci; 2024 Apr; 12(8):2007-2018. PubMed ID: 38456516
[No Abstract] [Full Text] [Related]
12. Noninvasive nanoparticle strategies for brain tumor targeting.
Sun C; Ding Y; Zhou L; Shi D; Sun L; Webster TJ; Shen Y
Nanomedicine; 2017 Nov; 13(8):2605-2621. PubMed ID: 28756093
[TBL] [Abstract][Full Text] [Related]
13. An in vitro and in vivo study of peptide-functionalized nanoparticles for brain targeting: The importance of selective blood-brain barrier uptake.
Bode GH; Coué G; Freese C; Pickl KE; Sanchez-Purrà M; Albaiges B; Borrós S; van Winden EC; Tziveleka LA; Sideratou Z; Engbersen JFJ; Singh S; Albrecht K; Groll J; Möller M; Pötgens AJG; Schmitz C; Fröhlich E; Grandfils C; Sinner FM; Kirkpatrick CJ; Steinbusch HWM; Frank HG; Unger RE; Martinez-Martinez P
Nanomedicine; 2017 Apr; 13(3):1289-1300. PubMed ID: 27884636
[TBL] [Abstract][Full Text] [Related]
14. Nanoparticles and the blood-brain barrier: advancing from in-vitro models towards therapeutic significance.
Mc Carthy DJ; Malhotra M; O'Mahony AM; Cryan JF; O'Driscoll CM
Pharm Res; 2015 Apr; 32(4):1161-85. PubMed ID: 25446769
[TBL] [Abstract][Full Text] [Related]
15. Nanoparticles as a Carrier System for Drug Delivery Across Blood Brain Barrier.
Sarkar A; Fatima I; Jamal QMS; Sayeed U; Khan MKA; Akhtar S; Kamal MA; Farooqui A; Siddiqui MH
Curr Drug Metab; 2017; 18(2):129-137. PubMed ID: 28088890
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo studies on gelatin-siloxane nanoparticles conjugated with SynB peptide to increase drug delivery to the brain.
Tian XH; Wei F; Wang TX; Wang P; Lin XN; Wang J; Wang D; Ren L
Int J Nanomedicine; 2012; 7():1031-41. PubMed ID: 22403486
[TBL] [Abstract][Full Text] [Related]
17. Active Targeting Towards and Inside the Brain based on Nanoparticles: A Review.
Rabiei M; Kashanian S; Samavati SS; Jamasb S; McInnes SJP
Curr Pharm Biotechnol; 2020; 21(5):374-383. PubMed ID: 31793421
[TBL] [Abstract][Full Text] [Related]
18. Solid lipid nanoparticles as a vehicle for brain-targeted drug delivery: two new strategies of functionalization with apolipoprotein E.
Neves AR; Queiroz JF; Weksler B; Romero IA; Couraud PO; Reis S
Nanotechnology; 2015 Dec; 26(49):495103. PubMed ID: 26574295
[TBL] [Abstract][Full Text] [Related]
19. Nanotechnology approaches for drug and small molecule delivery across the blood brain barrier.
Silva GA
Surg Neurol; 2007 Feb; 67(2):113-6. PubMed ID: 17254859
[TBL] [Abstract][Full Text] [Related]
20. Nanotech revolution for the anti-cancer drug delivery through blood-brain barrier.
Caraglia M; De Rosa G; Salzano G; Santini D; Lamberti M; Sperlongano P; Lombardi A; Abbruzzese A; Addeo R
Curr Cancer Drug Targets; 2012 Mar; 12(3):186-96. PubMed ID: 22268384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
